On the evening of April 28, Shandong Bailong Chuangyuan Bio-Tech Co.Ltd(605016) released the annual report for 2021. During the reporting period, the company achieved an operating revenue of 653 million yuan, a year-on-year increase of 30.77%; The net profit attributable to the shareholders of the listed company was 104 million yuan, a year-on-year increase of 9.34%; The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 953267 million yuan, a year-on-year increase of 7.38%; The basic earnings per share is 0.90 yuan / share. In addition, the company plans to distribute 0.85 yuan (including tax) to all shareholders for every 10 shares and increase 4 shares with capital reserve for every 10 shares.
Shandong Bailong Chuangyuan Bio-Tech Co.Ltd(605016) is mainly engaged in the R & D, production and sales of prebiotic series products, dietary fiber series products, other starch sugar (alcohol) products and health sweetener products. The income contribution of prebiotic products and dietary fiber products accounts for a large proportion, and the industry has broad development prospects, which is the focus of the company's future business development; The healthy sweetener products benefited from the rapid growth of alodonose products in the overseas market. In 2021, the sales revenue has reached 829966 million yuan, accounting for 13.00% of the main business revenue. It is one of the important sources of new revenue and profit of the company; Other starch sugar (alcohol) products are an important supplement to the company's revenue except prebiotics, dietary fiber and health sweeteners.
The company said that the long-term strategic goal of the company is to implement "standardized" management and strive to create a standardized mode of operation standardization, process procedure, management data, talent specialization, marketing position and team humanization; Implement brand strategy, make full use of brand advantages, network advantages, R & D advantages and management advantages, strengthen horizontal cooperation in the industry, expand the business scale and variety range of enterprises, and consolidate and improve the position of prebiotics and dietary fiber products in the industry; Implement the innovative development strategy, build independent brands, improve the scientific and technological content of products, reduce production costs and improve the core competitiveness of enterprises.
In 2022, the company will continue to increase the production and sales of high-end products, meet the differentiated needs of customers and expand the product industry. Adhering to the business development concept of "people-oriented, integrity, mutual win-win, unity and cooperation and continuous innovation", taking biotechnology as the core, adhering to the development strategy of "research generation, development generation, reserve generation and production generation", adhering to the company's main business, continue to actively explore product ingredients, realize technological innovation and development, continue to increase cooperation with universities and scientific research institutes, and study the physiological functional characteristics of various products, According to its characteristics, on the one hand, develop its application fields and expand market demand; on the other hand, develop one or two or even multiple functional sugars, and conduct nutritional testing on them, so as to develop terminal products suitable for special people, extend the industrial chain, improve the comprehensive competitiveness of enterprises and avoid product homogenization. Improve the common technology of traditional production process and further improve the comprehensive utilization rate of raw and auxiliary materials.
